Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Decreases By 12.2%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 151,500 shares, a drop of 12.2% from the November 15th total of 172,500 shares. Based on an average daily trading volume, of 83,100 shares, the days-to-cover ratio is presently 1.8 days.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of large investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $40,000. Magnolia Capital Advisors LLC bought a new stake in DiaMedica Therapeutics in the second quarter valued at $87,000. Blue Trust Inc. acquired a new position in shares of DiaMedica Therapeutics during the third quarter valued at $185,000. Geode Capital Management LLC grew its position in shares of DiaMedica Therapeutics by 29.6% during the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after acquiring an additional 70,070 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after acquiring an additional 211,351 shares during the period. Institutional investors own 10.12% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

DiaMedica Therapeutics Stock Down 4.6 %

Shares of NASDAQ:DMAC traded down $0.26 on Friday, reaching $5.38. 86,668 shares of the company’s stock were exchanged, compared to its average volume of 58,901. DiaMedica Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $5.74. The business’s 50-day moving average is $4.62 and its two-hundred day moving average is $3.85. The firm has a market capitalization of $230.05 million, a price-to-earnings ratio of -9.61 and a beta of 1.51.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.